WHITE PAPER
The Impact of Biosimilar Competition in Europe 2021
Dec 16, 2021
Download

The 7th iteration of the 'Impact of Biosimilar Competition in Europe' report describes the effects on price, volume, and market share following the arrival of biosimilar competition in Europe. The report consists of observations on competitive markets, and a set of Key Performance Indicators (KPIs) to monitor the impact of biosimilars in 23 European markets.

Biologic medicines are an increasingly important component of pharmaceutical expenditure, due to their efficacy as treatments for complex conditions. Biologics represent 34% of medicine spending in Europe at list prices, reaching €8.8 billion in 2021, and growing at a 10.5% compound annual growth rate (CAGR) over the past five years. This compares to a 5.1% CAGR for the total market comprising small molecules, biologics, and biosimilar competitors. It is therefore critical to healthcare system sustainability to ensure that the impact of biosimilar competition is managed effectively. IQVIA’s 5 observations on the impact of biosimilar competition explore this and cover:

  1. The impact of COVID-19 on the biologics market
  2. The level of savings generated in 2021
  3. How access to biologic medicines has developed
  4. The market landscape and competition in Europe
  5. The future opportunity for manufacturers and payers
Contact Us